After a two-way media pitch, held a few weeks back between Group M and McCann, the former has bagged the Rs. 13-crore Boots Piramal Healthcare account. Till date, the account was under McCann's purview.
Boots Piramal, a 51:49 joint venture between the UK-based Boots Healthcare International and Nicholas Piramal India Ltd, offers an array of well-known brands like Strepsils (medicated sore throat lozenge) Ultra Clearasil (acne treatment cream), Icy (throat lozenge) and Sweetex (artificial sweetners.) BPHL is primarily focussed on developing a handful of high-turnover brands from its present kitty. Saridon with a Rs. 27-crore turnover is its biggest brand followed by Strepsils (at Rs. 16 crore), Polycrol (at Rs. 10 crore), Clearasil (at Rs. 7 crore) and Lacto Calamine (at Rs. 5 crore).
The company was in the news in recent past, with the relaunch of the 50-year-old brand of Ultra Clearasil. The relaunch was introduced with soft squeeze lamitube in a combination of red and blue, which was followed soon after by a new campaign devised by McCann Erickson.
When contacted, Group M officials refused to comment on the development.